These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17286521)

  • 21. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study.
    Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):371-2. PubMed ID: 16382376
    [No Abstract]   [Full Text] [Related]  

  • 22. NAMI perspective on CATIE: policy and research implications.
    Duckworth K; Fitzpatrick MJ
    Psychiatr Serv; 2008 May; 59(5):537-9. PubMed ID: 18451013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 24. CATIE and the value of atypical antipsychotics in the context of creating a recovery-oriented behavioral health system.
    Salzer MS; Evans AC
    Adm Policy Ment Health; 2006 Sep; 33(5):536-40. PubMed ID: 16773449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved patient care.
    Dynes JB
    Va Med Mon (1918); 1970 Feb; 97(2):135-7 passimass. PubMed ID: 4152569
    [No Abstract]   [Full Text] [Related]  

  • 26. Should the CATIE study be a wake-up call?
    Ragins M
    Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608
    [No Abstract]   [Full Text] [Related]  

  • 27. Interpretations and conclusions in the clinical trial.
    Docherty JP
    J Clin Psychiatry; 2001; 62 Suppl 9():40-3; discussion 44-5. PubMed ID: 11379831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving mental health treatments through comparative effectiveness research.
    Wang PS; Ulbricht CM; Schoenbaum M
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Optimization criteria for antipsychotic therapy: therapeutic margin].
    Martínez Granados F; Pol Yangüas E
    Farm Hosp; 2004; 28(3):214-24. PubMed ID: 15222876
    [No Abstract]   [Full Text] [Related]  

  • 30. [Problems on FDA phase IV drug evaluation of antipsychotic agents].
    Kazematsuri G
    Seishin Shinkeigaku Zasshi; 1990; 92(9):592-6. PubMed ID: 1980370
    [No Abstract]   [Full Text] [Related]  

  • 31. Schizophrenia therapy: beyond atypical antipsychotics.
    Snyder EM; Murphy MR
    Nat Rev Drug Discov; 2008 Jun; 7(6):471-2. PubMed ID: 18483482
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
    Kane JM
    J Clin Psychiatry; 2006 May; 67(5):831-2. PubMed ID: 16841634
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
    Swartz MS; Perkins DO; Stroup TS; McEvoy JP; Nieri JM; Haak DC
    Schizophr Bull; 2003; 29(1):33-43. PubMed ID: 12908659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of schizophrenia drugs often favors firm funding study.
    Vendantam S
    Washington Post; 2006 Apr; ():A1, A6. PubMed ID: 16856276
    [No Abstract]   [Full Text] [Related]  

  • 36. Report on the fifth consensus conference: methodology of long-term clinical trials in psychiatry.
    Angst J; Bech P; Bruinvels J; Engel RR; Ferner U; Guelfi JD; Lingjaerde O; Müller-Oerlinghausen B; Paes de Sousa M; Paykel E
    Pharmacopsychiatry; 1994 May; 27(3):101-7. PubMed ID: 8078950
    [No Abstract]   [Full Text] [Related]  

  • 37. [Determination of methylnicotinamide in the blood and urine as a means of controlling neuroleptic treatment effectiveness].
    Mys'ko GN
    Vrach Delo; 1982 Jan; (1):98-9. PubMed ID: 6122307
    [No Abstract]   [Full Text] [Related]  

  • 38. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.
    Keefe RS; Mohs RC; Bilder RM; Harvey PD; Green MF; Meltzer HY; Gold JM; Sano M
    Schizophr Bull; 2003; 29(1):45-55. PubMed ID: 12908660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacological treatments of schizophrenia.
    Simpson GM
    Psychopharmacol Bull; 1986; 22(1):33-5, 42-3. PubMed ID: 2873617
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.